Logo

Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

Share this

Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

Shots:

  • The P-IIb/III DIVERSITY study involve assessing of Pradaxa vs SOC (heparin or vitamin K antagonist) in children with acute VTE requiring anticoagulation therapy for 3mos. aged ≤18yrs. resulted in non-inferiority to the SOC in pediatric patients at high risk of VTE with comparable bleeding rates
  • The P-III second study assess direct oral anticoagulant (DOAC) for the secondary prevention of VTE in ~200 children with persistent VTE risk factors for 12mos. resulted in the reduction of recurrent VTEs and major bleeding event
  • Pradaxa (PO) is an anticoagulant indicated to treat & prevent blood clots and stroke in people with atrial fibrillation with its safety & efficacy proven in RE-VOLUTION study in adults with VTE

Click here to read full press release/ article | Ref: PRNewswire | Image: Blue Sky Exhibits


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions